<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1527">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04518410</url>
  </required_header>
  <id_info>
    <org_study_id>A5401/ACTIV-2</org_study_id>
    <secondary_id>38742</secondary_id>
    <nct_id>NCT04518410</nct_id>
  </id_info>
  <brief_title>ACTIV-2: A Study for Outpatients With COVID-19</brief_title>
  <official_title>Adaptive Platform Treatment Trial for Outpatients With COVID-19 (Adapt Out COVID)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>AIDS Clinical Trials Group</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Drug studies often look at the effect one or two drugs have on a medical condition, and
      involve one company. There is currently an urgent need for one study to efficiently test
      multiple drugs from more than one company, in people who have tested positive for COVID-19
      but who do not currently need hospitalization. This could help prevent disease progression to
      more serious symptoms and complications, and spread of COVID-19 in the community.

      This study looks at the safety and effectiveness of different drugs in treating COVID-19 in
      outpatients. Participants in the study will be treated with either a study drug or with
      placebo.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a master protocol to evaluate the safety and efficacy of multiple investigational
      agents aimed at modifying the host immune response to SARS-CoV-2 infection, or directly
      enhancing viral control in order to limit disease progression.

      The study is designed to transition from phase 2 to phase 3 in the same trial, with or
      without a pause in enrollment, depending on the speed of enrollment and interim results. For
      promising agents with limited availability, a phase 3 evaluation may occur at a later time.
      Up to two dose levels of the same agent may be assessed. Agents may also enter directly into
      phase 3 evaluation if sufficient safety and efficacy data are available from outside the
      trial.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 19, 2020</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Unblinded data will be provided to the Data and Safety Monitoring Board for interim analyses. Unblinded Day 28 data will also be provided to a small group of people from the company who owns the investigational agent, to assist the company in deciding if the agent should move into phase 3 evaluation; or in choosing a dose of their agent to move into phase 3 evaluation.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Duration of COVID-19 symptoms (Phase 2)</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Symptoms: Fever or feeling feverish; cough, shortness of breath or difficulty breathing at rest or with activity; sore throat; body pain or muscle pain/aches; fatigue; headache, chills, nasal obstruction or congestion; nasal discharge (runny nose); nausea or vomiting; and diarrhea. Each symptom is scored daily by the participant as absent (score 0), mild (1), moderate (2) or severe (3)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-treatment presence of SARS-CoV-2 RNA at Day 3 (Phase 2)</measure>
    <time_frame>Day 3</time_frame>
    <description>Measured as detectable or undetectable, from site-collected NP (nasopharyngeal) swabs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-treatment presence of SARS-CoV-2 RNA at Day 7 (Phase 2)</measure>
    <time_frame>Day 7</time_frame>
    <description>Measured as detectable or undetectable, from site-collected NP (nasopharyngeal) swabs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-treatment presence of SARS-CoV-2 RNA at Day 14 (Phase 2)</measure>
    <time_frame>Day 14</time_frame>
    <description>Measured as detectable or undetectable, from site-collected NP (nasopharyngeal) swabs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-treatment presence of SARS-CoV-2 RNA at Day 21 (Phase 2)</measure>
    <time_frame>Day 21</time_frame>
    <description>Measured as detectable or undetectable, from site-collected NP (nasopharyngeal) swabs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Post-treatment presence of SARS-CoV-2 RNA at Day 28 (Phase 2)</measure>
    <time_frame>Day 28</time_frame>
    <description>Measured as detectable or undetectable, from site-collected NP (nasopharyngeal) swabs</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of new adverse event (AE) ≥ Grade 3 (Phase 2)</measure>
    <time_frame>Thru Day 28</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cumulative incidence of death from any cause or hospitalization (Phase 3)</measure>
    <time_frame>Thru Day 28</time_frame>
    <description>≥24 hours of acute care in a hospital or similar acute care facility, including Emergency Rooms or temporary facilities instituted ton address medical needs of those with severe COVID-19</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of participants with new adverse event (AE) ≥ Grade 3 (Phase 3)</measure>
    <time_frame>Thru Day 28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of death from any cause or hospitalization (Phase 2)</measure>
    <time_frame>Thru Day 28</time_frame>
    <description>≥24 hours of acute care in a hospital or similar acute care facility, including Emergency Rooms or temporary facilities instituted ton address medical needs of those with severe COVID-19</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of COVID-19 symptoms (Phase 3)</measure>
    <time_frame>Up to Day 28</time_frame>
    <description>Symptoms: Fever or feeling feverish; cough, shortness of breath or difficulty breathing at rest or with activity; sore throat; body pain or muscle pain/aches; fatigue; headache, chills, nasal obstruction or congestion; nasal discharge (runny nose); nausea or vomiting; and diarrhea. Each symptom is scored daily by the participant as absent (score 0), mild (1), moderate (2) or severe (3)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of SARS-CoV-2 RNA (Phases 2 and 3)</measure>
    <time_frame>Thru Day 28</time_frame>
    <description>Measured as detectable or undetectable, from participant-collected nasal swabs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of SARS-Cov-2 RNA (Phases 2 and 3)</measure>
    <time_frame>Thru Day 28</time_frame>
    <description>Measured from participant-collected nasal swabs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>COVID-19 severity ranking (Phases 2 and 3)</measure>
    <time_frame>From Day 0 thru Day 28</time_frame>
    <description>Based on symptom severity scores. Symptoms: Fever or feeling feverish; cough, shortness of breath or difficulty breathing at rest or with activity; sore throat; body pain or muscle pain/aches; fatigue; headache, chills, nasal obstruction or congestion; nasal discharge (runny nose); nausea or vomiting; and diarrhea. Each symptom is scored daily by the participant as absent (score 0), mild (1), moderate (2) or severe (3). For participants who are alive at 28 days and not previously hospitalized, the severity ranking will be based on the area under the curve (AUC) of the symptom score associated with COVID-19 disease over time. Participants hospitalized or who die during follow-up through 28 days will be ranked as worse than those alive and never hospitalized as follows (in worsening rank order): alive and not hospitalized at 28 days; hospitalized but alive at 28 days; and died at or before 28 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of ≥1 worsening symptom of COVID-19 (Phases 2 and 3)</measure>
    <time_frame>Thru Day 28</time_frame>
    <description>Progression of one or more COVID-19-associated symptoms to a worse status than recorded at study entry, prior to start of investigational product or placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of fever (Phases 2 and 3)</measure>
    <time_frame>Thru Day 28</time_frame>
    <description>Defined as the last day in the participant's study diary on which a temperature ≥ 38°C (100.4°F) was recorded or a potentially antipyretic drug was taken.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to self-report return to usual (pre-COVID-19) health (Phases 2 and 3)</measure>
    <time_frame>Thru Day 28</time_frame>
    <description>As recorded in participant's study diary</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cumulative incidence of death from any cause or hospitalization (Phases 2 and 3)</measure>
    <time_frame>Day 0 thru Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxygen saturation level (Phase 2)</measure>
    <time_frame>Thru Day 28</time_frame>
    <description>Measured by pulse oximeter and categorized as &lt;96% versus ≥96%</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of SARS-CoV-2 RNA from site-collected NP swabs (Phase 2)</measure>
    <time_frame>Days 0, 3, 7, 14, 21 and 28</time_frame>
    <description>Measured by AUC and above assay lower limit of quantification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of SARS-CoV-2 RNA from saliva (Phase 2)</measure>
    <time_frame>Days 0, 3, 7, 14, 21 and 28</time_frame>
    <description>Measured by AUC and above assay lower limit of quantification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of SARS-CoV-2 RNA from self-collected nasal swabs (Phase 2)</measure>
    <time_frame>Daily at Days 0-14, plus Days 21 and 28</time_frame>
    <description>Measured by AUC and above assay lower limit of quantification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of SARS-CoV-2 RNA (Phase 2)</measure>
    <time_frame>Days 3, 7, 14, 21 and 28</time_frame>
    <description>From site-collected NP swabs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-treatment presence of SARS-CoV-2 RNA in saliva (Phase 2)</measure>
    <time_frame>Days 3, 7, 14, 21 and 28</time_frame>
    <description>Measured as detectable or undetectable</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-treatment level of SARS-CoV-2 RNA (Phase 2)</measure>
    <time_frame>Days 3, 7, 14, 21 and 28</time_frame>
    <description>Measured from saliva samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of new adverse event (AE) ≥ Grade 3 (Phase 3)</measure>
    <time_frame>Thru Week 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of investigational agent (Phase 2 - LY3819253)</measure>
    <time_frame>Days 0, 14, 28, Week 12, Week 24</time_frame>
    <description>Analyses of plasma samples collected from placebo-treated participants are not planned</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of anti-drug antibodies (Phase 2 - LY3819253)</measure>
    <time_frame>Days 0, 14, 28, Week 12, Week 24</time_frame>
    <description>Analyses of plasma samples collected from placebo-treated participants are not planned</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC (Phase 2 - LY3819253)</measure>
    <time_frame>Days 0, 14, 28, Week 12, Week 24</time_frame>
    <description>Area under the concentration-time curve. Analyses of plasma samples collected from placebo-treated participants are not planned</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total body clearance (CL) (Phase 2 - LY3819253)</measure>
    <time_frame>Days 0, 14, 28, Week 12, Week 24</time_frame>
    <description>Analyses of plasma samples collected from placebo-treated participants are not planned</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Elimination half-life (Phase 2 - LY3819253)</measure>
    <time_frame>Days 0, 14, 28, Week 12, Week 24</time_frame>
    <description>T1/2. Analyses of plasma samples collected from placebo-treated participants are not planned</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmax (Phase 2 - LY3819253)</measure>
    <time_frame>Days 0, 14, 28, Week 12, Week 24</time_frame>
    <description>Maximum plasma concentration of LY3819253. Analyses of samples collected from placebo-treated participants are not planned</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin (Phase 2 - LY3819253)</measure>
    <time_frame>Days 0, 14, 28, Week 12, Week 24</time_frame>
    <description>Minimum plasma concentration of LY3819253. Analyses of samples collected from placebo-treated participants are not planned</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Coronavirus</condition>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>ACTIV-2 Drug</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this study will be randomized to receive ACTIV2 Drug or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo arm may be pooled across more than one experimental arm if multiple investigational drugs are available to be tested at the same time. If it is not possible to use matching placebo over more than one experimental arm, additional placebo arms will be included in the study</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3819253</intervention_name>
    <description>Administered by IV infusion</description>
    <arm_group_label>ACTIV-2 Drug</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Commercially available 0.9% sodium chloride solution. Administered by IV infusion</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent.

          -  Positive test for COVID-19 up to 7 days before participation in study.

          -  Able to begin study treatment no later than 10 days from self-reported onset of
             COVID-19 related symptom(s):

               -  fever or feeling feverish

               -  cough

               -  shortness of breath or difficulty breathing at rest or when active

               -  sore throat

               -  body pain or muscle pain/aches

               -  fatigue

               -  headache

               -  chills

               -  blocked nose/nasal congestion

               -  runny nose

               -  loss of taste or smell

               -  nausea or vomiting

               -  diarrhea

               -  temperature ≥ 38°C (100.4°F)

          -  One or more of the following signs/symptoms within 48 hours of participating in the
             study:

               -  fever or feeling feverish

               -  cough

               -  shortness of breath or difficulty breathing at rest or when active

               -  sore throat

               -  body pain or muscle pain/aches

               -  fatigue

               -  headache

               -  chills

               -  blocked nose/nasal congestion

               -  runny nose

               -  loss of taste or smell

               -  nausea or vomiting

               -  diarrhea

               -  temperature ≥ 38°C (100.4°F)

          -  Oxygen levels of ≥92% when resting (measured by study staff within 48 hours of
             participating in the study), unless participant is receiving long-term supplementary
             oxygen for an underlying lung condition.

          -  Participant must agree not to participate in another clinical trial for the treatment
             of COVID-19 or SARS-CoV-2 during the study period until hospitalization or 28 days
             after the start of the study, whichever occurs first.

        Exclusion Criteria:

          -  History of or current hospitalization for COVID-19.

          -  Current need for hospitalization or immediate medical attention.

          -  Any use of the following medications up to 30 days before participating in the study:

               -  Hydroxychloroquine (except for long-term autoimmune diseases)

               -  Chloroquine and/or ivermectin (unless used for parasitic infection)

               -  Remdesivir, systemic and inhaled steroids (unless used for long-term conditions)

               -  HIV protease inhibitors (unless used long-term for HIV infection)

          -  Receipt of plasma from a person who recovered from COVID-19 any time before
             participating in the study.

          -  Receipt of a SARS-CoV-2 vaccine any time before participating in the study.

          -  Receipt of other investigational treatments for SARS-CoV-2 any time before
             participating in the study (not including drugs approved and taken for other
             conditions/diseases).

          -  Receipt of systemic steroids (e.g. prednisone, dexamethasone) or inhaled steroids up
             to 30 days before participating in the study, unless this is a stable dose for a
             long-term condition.

          -  Known allergy/sensitivity or hypersensitivity to study drug or placebo.

          -  Any condition requiring surgery up to 7 days before participating in the study, or
             that is considered life threatening up to 30 days before participating in the study.

        Other investigational drug protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Smith, MD, MAS</last_name>
    <role>Study Chair</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham (Site 1005), 908 20th Street South</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte Olivia Hague</last_name>
      <phone>205-975-4285</phone>
      <email>ohague@uabmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>UCLA CARE Center (Site 1003), 11075 Santa Monica Blvd., Suite 100</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90035</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Fortier</last_name>
      <phone>310-557-9640</phone>
      <email>sfortier@mednet.ucla.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California San Diego (Site 1002), 220 Dickinson Street</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92103</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Hendrickx</last_name>
      <phone>619-543-6968</phone>
      <email>smhendrickx@health.ucsd.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California San Francisco (Site 1009), 995 Potrero Ave., Building 80, Ward 84</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jay Dwyer</last_name>
      <phone>415-476-4082</phone>
      <email>jay.dwyer@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Harbor UCLA (Site 1022), 1124 West Carson Street</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mario Guerrero</last_name>
      <phone>424-201-3000</phone>
      <phone_ext>7318</phone_ext>
      <email>mguerrero@lundquist.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Colorado (Site 1007), 12401 East 17th Avenue</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Suzanne Fiorillo</last_name>
      <phone>303-724-5931</phone>
      <email>Suzanne.Fiorillo@cuanschutz.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AGA Clinical Trials (Site 1026), 900 West 49th Street</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33012</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roberto Aguirre</last_name>
      <phone>305-819-6990</phone>
      <phone_ext>8004</phone_ext>
      <email>raguirre@agaclinicaltrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The Ponce de Leon Center (site 1015), 341 Ponce De Leon Avenue Northeast</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ericka Patrick</last_name>
      <phone>404-616-6313</phone>
      <email>erpatri@emory.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Agile Clinical Rsearch Trials, LLC (Site 1051), 750 Hammond Drive</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30328</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shauna Marshall</last_name>
      <phone>770-573-4109</phone>
      <email>marshall@agilecrt.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Northwestern University (Site 1025), 645 North Michigan Ave</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baiba Berzins</last_name>
      <phone>312-695-5012</phone>
      <email>baiba@northwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center (Site 1017), 600 Paulina St.</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joan Swiatek</last_name>
      <phone>312-942-6017</phone>
      <email>Joan_Swiatek@rush.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center (Site 1042), 3901 Rainbow Boulevard</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luigi Boccardi</last_name>
      <phone>913-588-4022</phone>
      <email>lboccardi@kumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New Orleans Adolescent Trials Unit (Site 1028), 1440 Canal St., Suite 904</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112-2703</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emily Callegari</last_name>
      <phone>504-988-1467</phone>
      <email>ecallegari@tulane.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University (Site 1006), 1830 East Monument Street</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Becky Becker</last_name>
      <phone>410-614-4036</phone>
      <email>Rbecke22@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital (Site 1016), 55 Fruit Street</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theresa Flynn</last_name>
      <phone>617-724-0072</phone>
      <email>tflynn@partners.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine (Site 1008), 620 South Taylor, Suite 200</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Kessels</last_name>
      <phone>314-747-1096</phone>
      <email>lkessels@wustl.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Columbia University Irving Medical Center (Site 1019), 180 Fort Washington Avenue</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brit Sovic</last_name>
      <phone>212-305-2201</phone>
      <email>bws2125@cumc.columbia.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cornell Clinical Trials Unit (Site 1011), NewYork-Presbyterian Hospital-Weill Cornell Medical Center, 525 East 68th Street</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Valery Hughes</last_name>
      <phone>646-246-8327</phone>
      <email>vah9001@med.cornell.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of North Carolina at Chapel Hill (Site 1001), 130 Mason Farm Rd., Bioinformatics Bldg, 2nd Floor</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Becky Straub</last_name>
      <phone>919-843-9975</phone>
      <email>becky_straub@med.unc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ohio State University Medical Center (Site 1020), 480 Medical Center Drive</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kathy Watson</last_name>
      <phone>614-293-8112</phone>
      <email>kathy.watson@osumc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cincinnati CRS (Site 1004), University of Cincinnati, University Hospital, 200 Albert Sabin Way</name>
      <address>
        <city>Ohio City</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sharon Kohrs</last_name>
      <phone>513-584-6383</phone>
      <email>kohrssd@ucmail.uc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania (Site 1031), 3400 Spruce Street</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miranda Mastellone</last_name>
      <phone>267-819-8608</phone>
      <email>miranda.mastellone@pennmedicine.upenn.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Pittsburgh (Site 1018), 3471 5th Ave.</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213-3215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Renee Weinman</last_name>
      <phone>412-383-1748</phone>
      <email>drw38@pitt.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Therapeutics Clinical Research (Site 1013), Vanderbilt Health One Hundred Oaks, 719 Thompson Ln., Ste 47183</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37204-4718</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beverly Woddward</last_name>
      <phone>615-936-8516</phone>
      <email>beverly.o.woodward@vumc.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sealy Institute for Vaccine Sciences Clincial Trials Program (Site 1044), 400 Harborside Drive</name>
      <address>
        <city>Galveston</city>
        <state>Texas</state>
        <zip>77555-0001</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerianne Casey</last_name>
      <phone>409-772-5278</phone>
      <email>gecasey@utmb.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Lyndon B. Johnson Hospital (Site 1014), 5656 Kelley Street</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77026-1967</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Damian A Chiandussi</last_name>
      <phone>713-500-5512</phone>
      <email>damian.a.chiandussi@uth.tmc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Washington ACTU (Site 1012), Harborview Medical Center, 325 9th Ave.</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chris Jonsson</last_name>
      <phone>206-744-8886</phone>
      <email>cjonsson@uw.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Puerto Rico AIDS Clinical Trials Unit (Site 1024), Proyecto ACTU Biomedical Building II</name>
      <address>
        <city>San Juan</city>
        <zip>00935</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marielly López-Rivera</last_name>
      <phone>787-767-9192</phone>
      <email>marielly.lopez@upr.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>Puerto Rico</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <link>
    <url>https://www.cdc.gov/coronavirus/2019-nCoV/index.html</url>
    <description>CDC (Centers for Disease Control and Prevention): Coronavirus (COVID-19) website</description>
  </link>
  <link>
    <url>https://www.niaid.nih.gov/clinical-trials/participant-guide</url>
    <description>A Participant's Guide to Clinical Trials (NIAID)</description>
  </link>
  <link>
    <url>https://www.niaid.nih.gov/clinical-trials/find-a-clinical-trial</url>
    <description>Find a Clinical Trial (NIAID)</description>
  </link>
  <link>
    <url>https://www.niaid.nih.gov/clinical-trials</url>
    <description>Clinical Trials at NIAID</description>
  </link>
  <link>
    <url>https://www.niaid.nih.gov/</url>
    <description>National Institute for Allergy and Infectious Diseases (NIAID)</description>
  </link>
  <link>
    <url>https://www.covid19treatmentguidelines.nih.gov/</url>
    <description>NIH COVID-19 treatment guidelines</description>
  </link>
  <link>
    <url>https://www.who.int/emergencies/diseases/novel-coronavirus-2019/</url>
    <description>WHO COVID-19 treatment guidelines</description>
  </link>
  <link>
    <url>https://www.nih.gov/research-training/medical-research-initiatives/activ</url>
    <description>NIH: Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)</description>
  </link>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 17, 2020</study_first_submitted>
  <study_first_submitted_qc>August 18, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2020</study_first_posted>
  <last_update_submitted>September 30, 2020</last_update_submitted>
  <last_update_submitted_qc>September 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Coronavirus</keyword>
  <keyword>COVID 19</keyword>
  <keyword>Coronaviridae Infections</keyword>
  <keyword>Coronavirus Infections</keyword>
  <keyword>RNA Virus Infections</keyword>
  <keyword>Virus Diseases</keyword>
  <keyword>Nidovirales Infections</keyword>
  <keyword>SARS-CoV-2</keyword>
  <keyword>SARS Coronavirus</keyword>
  <keyword>ACTIV-2</keyword>
  <keyword>ACTIV2</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

